Liraglutide monotherapy and add on therapy on obese women with polycystic ovarian syndromes: a systematic review and meta-analysis.

Tian D, Chen W, Xu Q, Li X, Lv Q

Minerva medica8 Feb 2021Cited by 7 (Europe PMC)

PMID33555153DOI10.23736/s0026-4806.21.07085-3PepBankPUB-33555153

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanSystematic reviewEfficacy outcome
In obese women with PCOS, pooled liraglutide monotherapy or add-on therapy significantly reduced waist circumference by 6.28 cm.
In plain wordsIn obese women with PCOS, waist size fell after liraglutide, alone or added to other treatment.
Peptide
Liraglutide
Outcome
DecreaseWaist circumference
Study
n = 401
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Measurements
Pooled change in waist circumference
−6.28 cm
liraglutide monotherapy or add-on
Source sentences
Summary
Waist circumference, BMI, weight was significantly reduced by -6.28 cm (95% CI: -7.89, -4.67; P2 (95% CI: -2.79, -2.27; P<0.00001) and -4.33 kg (95% CI: -6.05, -2.61; P<0.00001) after treatment with liraglutide monotherapy or add on therapy.
2 context sentences(design, population, supporting numbers)
Summary · context
A total of six studies with 401 women were included in this research.
Summary · context
For women with PCOS, BMI, weight, and waist circumference were significantly decreased after 12~24 weeks of treatment with liraglutide monotherapy and add-on therapy.
Report a problemFND-3355515301
02HumanSystematic reviewEfficacy outcome
In obese women with PCOS, pooled liraglutide monotherapy or add-on therapy significantly reduced BMI by 2.53 kg/m2.
In plain wordsIn obese women with PCOS, BMI fell after liraglutide, alone or added to other treatment.
Peptide
Liraglutide
Outcome
DecreaseBMI
Study
n = 401
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Measurements
Pooled change in BMI
−2.53 kg/m2
liraglutide monotherapy or add-on
Source sentences
Summary
Waist circumference, BMI, weight was significantly reduced by -6.28 cm (95% CI: -7.89, -4.67; P2 (95% CI: -2.79, -2.27; P<0.00001) and -4.33 kg (95% CI: -6.05, -2.61; P<0.00001) after treatment with liraglutide monotherapy or add on therapy.
2 context sentences(design, population, supporting numbers)
Summary · context
A total of six studies with 401 women were included in this research.
Summary · context
For women with PCOS, BMI, weight, and waist circumference were significantly decreased after 12~24 weeks of treatment with liraglutide monotherapy and add-on therapy.
Report a problemFND-3355515302
03HumanSystematic reviewEfficacy outcome
In obese women with PCOS, pooled liraglutide monotherapy or add-on therapy significantly reduced body weight by 4.33 kg.
In plain wordsIn obese women with PCOS, body weight fell after liraglutide, alone or added to other treatment.
Peptide
Liraglutide
Outcome
DecreaseBody weight
Study
n = 401
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Measurements
Pooled change in weight
−4.33 kg
liraglutide monotherapy or add-on
Source sentences
Summary
Waist circumference, BMI, weight was significantly reduced by -6.28 cm (95% CI: -7.89, -4.67; P2 (95% CI: -2.79, -2.27; P<0.00001) and -4.33 kg (95% CI: -6.05, -2.61; P<0.00001) after treatment with liraglutide monotherapy or add on therapy.
2 context sentences(design, population, supporting numbers)
Summary · context
A total of six studies with 401 women were included in this research.
Summary · context
For women with PCOS, BMI, weight, and waist circumference were significantly decreased after 12~24 weeks of treatment with liraglutide monotherapy and add-on therapy.
Report a problemFND-3355515303
04HumanSystematic reviewEfficacy outcome
In obese women with PCOS, HOMA-IR fell moderately after liraglutide treatment (-0.81).
In plain wordsIn obese women with PCOS, a measure of insulin resistance fell moderately after liraglutide.
Peptide
Liraglutide
Outcome
DecreaseHOMA-IR
Study
n = 401
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Measurements
Pooled change in HOMA-IR
−0.81 score
liraglutide
Source sentences
Summary
There was a moderate declination in HOMA-IR scores following liraglutide treatment with -0.81 (95% CI: -0.97, -0.64; P<0.00001).
2 context sentences(design, population, supporting numbers)
Summary · context
A total of six studies with 401 women were included in this research.
Summary · context
For women with PCOS, BMI, weight, and waist circumference were significantly decreased after 12~24 weeks of treatment with liraglutide monotherapy and add-on therapy.
Report a problemFND-3355515304
05HumanSystematic reviewEfficacy outcome
In obese women with PCOS, FSH declined in the liraglutide group, with high heterogeneity.
In plain wordsIn obese women with PCOS, FSH levels fell in the liraglutide group, but results varied widely between studies.
Peptide
Liraglutide
Outcome
DecreaseFSH
Study
n = 401
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
Dose not stated
Source sentences
Summary
FSH and LH show a decline in the liraglutide group with high heterogeneity (I²>95%).
2 context sentences(design, population, supporting numbers)
Summary · context
A total of six studies with 401 women were included in this research.
Summary · context
For women with PCOS, BMI, weight, and waist circumference were significantly decreased after 12~24 weeks of treatment with liraglutide monotherapy and add-on therapy.
Report a problemFND-3355515305
06HumanSystematic reviewEfficacy outcome
In obese women with PCOS, LH declined in the liraglutide group, with high heterogeneity.
In plain wordsIn obese women with PCOS, LH levels fell in the liraglutide group, but results varied widely between studies.
Peptide
Liraglutide
Outcome
DecreaseLH
Study
n = 401
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
Dose not stated
Source sentences
Summary
FSH and LH show a decline in the liraglutide group with high heterogeneity (I²>95%).
2 context sentences(design, population, supporting numbers)
Summary · context
A total of six studies with 401 women were included in this research.
Summary · context
For women with PCOS, BMI, weight, and waist circumference were significantly decreased after 12~24 weeks of treatment with liraglutide monotherapy and add-on therapy.
Report a problemFND-3355515306

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.